157 related articles for article (PubMed ID: 36064196)
1. Large cell neuroendocrine carcinoma of the lung controlled for 4 years by a single administration of pembrolizumab: A case report.
Watanabe M; Matsumura Y; Yamaguchi H; Mine H; Takagi H; Ozaki Y; Fukuhara M; Muto S; Okabe N; Shio Y; Suzuki H
Thorac Cancer; 2022 Oct; 13(19):2817-2822. PubMed ID: 36064196
[TBL] [Abstract][Full Text] [Related]
2. Complete and durable response of pulmonary large-cell neuroendocrine carcinoma to pembrolizumab.
Kadota N; Hatakeyama N; Hino H; Kunishige M; Kondo Y; Okano Y; Machida H; Naruse K; Shinohara T; Sakiyama S; Ogushi F; Takeuchi E
Cancer Rep (Hoboken); 2022 Aug; 5(8):e1589. PubMed ID: 34817132
[TBL] [Abstract][Full Text] [Related]
3. Clinical activity of pembrolizumab with or without chemotherapy in advanced pulmonary large-cell and large-cell neuroendocrine carcinomas: a multicenter retrospective cohort study.
Song L; Zhou F; Xu T; Zeng L; Xia Q; Wang Z; Deng L; Li Y; Qin H; Yan H; Huang Z; Mi J; Xu Q; Yang N; Zhou C; Zhang Y
BMC Cancer; 2023 May; 23(1):443. PubMed ID: 37189075
[TBL] [Abstract][Full Text] [Related]
4. Long-term survivor of pulmonary combined large cell neuroendocrine carcinoma treated with nivolumab.
Oda R; Okuda K; Yamashita Y; Sakane T; Tatematsu T; Yokota K; Endo K; Nakanishi R
Thorac Cancer; 2020 Jul; 11(7):2036-2039. PubMed ID: 32379390
[TBL] [Abstract][Full Text] [Related]
5. Pulmonary large cell carcinoma, highly positive for PD-L1, shows marked response to pembrolizumab: A case report.
Okabe N; Mine H; Takagi H; Watanabe M; Muto S; Matsumura Y; Shio Y; Suzuki H
Thorac Cancer; 2021 Apr; 12(7):1141-1144. PubMed ID: 33605014
[TBL] [Abstract][Full Text] [Related]
6. A clinicopathological study of peripheral, small-sized high-grade neuroendocrine tumours of the lung: differences between small-cell lung carcinoma and large-cell neuroendocrine carcinoma.
Isaka M; Nakagawa K; Ohde Y; Okumura T; Watanabe R; Ito I; Nakajima T; Kondo H
Eur J Cardiothorac Surg; 2012 Apr; 41(4):841-6. PubMed ID: 22219429
[TBL] [Abstract][Full Text] [Related]
7. Multicentre phase II study of cisplatin-etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study.
Le Treut J; Sault MC; Lena H; Souquet PJ; Vergnenegre A; Le Caer H; Berard H; Boffa S; Monnet I; Damotte D; Chouaid C
Ann Oncol; 2013 Jun; 24(6):1548-52. PubMed ID: 23406729
[TBL] [Abstract][Full Text] [Related]
8. Combination chemotherapy with irinotecan and cisplatin for large-cell neuroendocrine carcinoma of the lung: a multicenter phase II study.
Niho S; Kenmotsu H; Sekine I; Ishii G; Ishikawa Y; Noguchi M; Oshita F; Watanabe S; Nakajima R; Tada H; Nagai K
J Thorac Oncol; 2013 Jul; 8(7):980-4. PubMed ID: 23774385
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment with temozolomide in an elderly woman with advanced pulmonary large-cell neuroendocrine carcinoma: A case report.
Wei J; Dong XF; Hu ZL; Tang S; Lu YF
Medicine (Baltimore); 2018 Dec; 97(51):e13318. PubMed ID: 30572435
[TBL] [Abstract][Full Text] [Related]
10. Large Cell Neuroendocrine Carcinoma of the Mediastinum Successfully Treated with Systemic Chemotherapy after Palliative Radiotherapy.
Hidaka T; Okuzumi S; Matsuhashi A; Takahashi H; Hata K; Shimizu S; Iwasaki Y
Intern Med; 2019 Feb; 58(4):563-568. PubMed ID: 30333385
[TBL] [Abstract][Full Text] [Related]
11. Spontaneous regression of recurrent pulmonary large cell neuroendocrine carcinoma with alteration of PD-L1 expression after surgical resection: A case report.
Hong G; Chung C; Park D; Lee SI; Lee JE; Kang DH
Thorac Cancer; 2024 Jan; 15(3):266-270. PubMed ID: 38057657
[TBL] [Abstract][Full Text] [Related]
12. Heterogeneous Tumor-Immune Microenvironments between Primary and Metastatic Tumors in a Patient with
Tashiro T; Imamura K; Tomita Y; Tamanoi D; Takaki A; Sugahara K; Sato R; Saruwatari K; Sakata S; Inaba M; Ushijima S; Hirata N; Sakagami T
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352665
[TBL] [Abstract][Full Text] [Related]
13. Pathological diagnosis of pulmonary large cell neuroendocrine carcinoma by endobronchial ultrasound-guided transbronchial needle aspiration.
Inage T; Nakajima T; Fujiwara T; Sakairi Y; Wada H; Suzuki H; Iwata T; Chiyo M; Nakatani Y; Yoshino I
Thorac Cancer; 2018 Feb; 9(2):273-277. PubMed ID: 29271588
[TBL] [Abstract][Full Text] [Related]
14. Histological Transformation to Large Cell Neuroendocrine Carcinoma from Lung Adenocarcinoma Harboring an EGFR Mutation: An Autopsy Case Report.
Moriya R; Hokari S; Shibata S; Koizumi T; Tetsuka T; Ito K; Hashidate H; Tsukada H
Intern Med; 2017; 56(15):2013-2017. PubMed ID: 28768973
[TBL] [Abstract][Full Text] [Related]
15. Platinum Doublet plus Atezolizumab as First-line Treatment in Metastatic Large Cell Neuroendocrine Carcinoma: A Single Institution Experience.
Vrontis K; Economidou SC; Fotopoulos G
Cancer Invest; 2022 Feb; 40(2):124-131. PubMed ID: 34601985
[TBL] [Abstract][Full Text] [Related]
16. Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden.
Wang VE; Urisman A; Albacker L; Ali S; Miller V; Aggarwal R; Jablons D
J Immunother Cancer; 2017 Sep; 5(1):75. PubMed ID: 28923100
[TBL] [Abstract][Full Text] [Related]
17. Pulmonary pleomorphic carcinoma in an elderly patient treated with pembrolizumab shows a marked response.
Yamasaki M; Matsumoto Y; Nakamoto K; Hattori N
J Cancer Res Ther; 2021; 17(6):1580-1582. PubMed ID: 34916402
[TBL] [Abstract][Full Text] [Related]
18. Double primary lung carcinoma consisting of large cell neuroendocrine carcinoma and squamous cell carcinoma: report of a case.
Yamada Y; Iyoda A; Suzuki M; Mizobuchi T; Baba M; Hiroshima K; Ohwada H; Fujisawa T
Ann Thorac Cardiovasc Surg; 2005 Dec; 11(6):397-400. PubMed ID: 16401989
[TBL] [Abstract][Full Text] [Related]
19. Tropomyosin-related kinase B inhibitor has potential for tumor regression and relapse prevention in pulmonary large cell neuroendocrine carcinoma.
Odate S; Onishi H; Nakamura K; Kojima M; Uchiyama A; Kato M; Katano M
Anticancer Res; 2013 Sep; 33(9):3699-703. PubMed ID: 24023298
[TBL] [Abstract][Full Text] [Related]
20. Dramatic, significant metabolic response to a one-time pembrolizumab treatment following a relapse of pre-existing organizing pneumonia in a patient with advanced non-small cell lung cancer: A case report.
Kato M; Mori M; Miura K; Asao T; Motomura H; Nishino K; Ko R; Koyama R; Hayashi T; Takahashi K
Thorac Cancer; 2021 Nov; 12(22):3076-3079. PubMed ID: 34617405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
